Cargando…
Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma
BACKGROUND: Although current chemotherapy using bortezomib (Velcade) against multiple myeloma in adults has achieved significant responses and even remission, a majority of patients will develop acquired resistance to bortezomib. Increased thioredoxin level has been reported to be associated with ca...
Autores principales: | Zheng, Zhihong, Fan, Shengjun, Zheng, Jing, Huang, Wei, Gasparetto, Cristina, Chao, Nelson J., Hu, Jianda, Kang, Yubin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828316/ https://www.ncbi.nlm.nih.gov/pubmed/29482577 http://dx.doi.org/10.1186/s13045-018-0575-7 |
Ejemplares similares
-
Inhibition of Sphingosine Kinase 2 Results in PARK2-Mediated Mitophagy and Induces Apoptosis in Multiple Myeloma
por: Wu, Jian, et al.
Publicado: (2023) -
HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma
por: Lee, Sang Wu, et al.
Publicado: (2021) -
Combination treatment with 2-methoxyestradiol overcomes bortezomib resistance of multiple myeloma cells
por: Song, In-Sung, et al.
Publicado: (2013) -
Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone
por: Erath, Alexandra, et al.
Publicado: (2020) -
PINK1‐Dependent Mitophagy Regulates the Migration and Homing of Multiple Myeloma Cells via the MOB1B‐Mediated Hippo‐YAP/TAZ Pathway
por: Fan, Shengjun, et al.
Publicado: (2020)